These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 32043417

  • 1. Post hoc analyses of response rates to pharmacological treatments in children and adolescents with attention-deficit/hyperactivity disorder.
    Coghill DR, Newcorn JH, Chen J, Werner-Kiechle T, Banaschewski T.
    J Psychopharmacol; 2020 Aug; 34(8):874-882. PubMed ID: 32043417
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Randomized, Double-Blind, Placebo-Controlled Acute Comparator Trials of Lisdexamfetamine and Extended-Release Methylphenidate in Adolescents With Attention-Deficit/Hyperactivity Disorder.
    Newcorn JH, Nagy P, Childress AC, Frick G, Yan B, Pliszka S.
    CNS Drugs; 2017 Nov; 31(11):999-1014. PubMed ID: 28980198
    [Abstract] [Full Text] [Related]

  • 4. Treatment response and remission in a double-blind, randomized, head-to-head study of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit hyperactivity disorder.
    Dittmann RW, Cardo E, Nagy P, Anderson CS, Adeyi B, Caballero B, Hodgkins P, Civil R, Coghill DR.
    CNS Drugs; 2014 Nov; 28(11):1059-69. PubMed ID: 25038977
    [Abstract] [Full Text] [Related]

  • 5. Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.
    Roskell NS, Setyawan J, Zimovetz EA, Hodgkins P.
    Curr Med Res Opin; 2014 Aug; 30(8):1673-85. PubMed ID: 24627974
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of lisdexamfetamine dimesylate and atomoxetine in the treatment of attention-deficit/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study.
    Dittmann RW, Cardo E, Nagy P, Anderson CS, Bloomfield R, Caballero B, Higgins N, Hodgkins P, Lyne A, Civil R, Coghill D.
    CNS Drugs; 2013 Dec; 27(12):1081-92. PubMed ID: 23959815
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Review of lisdexamfetamine dimesylate in children and adolescents with attention deficit/hyperactivity disorder.
    Najib J, Didenko E, Meleshkina D, Yusupov K, Maw K, Ramnarain J, Tabassum M.
    Curr Med Res Opin; 2020 Oct; 36(10):1717-1735. PubMed ID: 32845786
    [Abstract] [Full Text] [Related]

  • 10. Long-term study of lisdexamfetamine dimesylate in Japanese children and adolescents with attention-deficit/hyperactivity disorder.
    Ichikawa H, Miyajima T, Yamashita Y, Fujiwara M, Fukushi A, Saito K.
    Neuropsychopharmacol Rep; 2020 Mar; 40(1):52-62. PubMed ID: 31814294
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Functional outcomes from a head-to-head, randomized, double-blind trial of lisdexamfetamine dimesylate and atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder and an inadequate response to methylphenidate.
    Nagy P, Häge A, Coghill DR, Caballero B, Adeyi B, Anderson CS, Sikirica V, Cardo E.
    Eur Child Adolesc Psychiatry; 2016 Feb; 25(2):141-9. PubMed ID: 25999292
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder and recent methylphenidate use.
    Jain R, Babcock T, Burtea T, Dirks B, Adeyi B, Scheckner B, Lasser R, Renna J, Duncan D.
    Adv Ther; 2013 May; 30(5):472-86. PubMed ID: 23681505
    [Abstract] [Full Text] [Related]

  • 14. Osmotic Release Oral System Methylphenidate Versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder in Chinese Youth: 8-Week Comparative Efficacy and 1-Year Follow-Up.
    Su Y, Yang L, Stein MA, Cao Q, Wang Y.
    J Child Adolesc Psychopharmacol; 2016 May; 26(4):362-71. PubMed ID: 26779845
    [Abstract] [Full Text] [Related]

  • 15. Phase II/III Study of Lisdexamfetamine Dimesylate in Japanese Pediatric Patients with Attention-Deficit/Hyperactivity Disorder.
    Ichikawa H, Miyajima T, Yamashita Y, Fujiwara M, Fukushi A, Saito K.
    J Child Adolesc Psychopharmacol; 2020 Feb; 30(1):21-31. PubMed ID: 31718254
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Developing a Risk Score to Guide Individualized Treatment Selection in Attention Deficit/Hyperactivity Disorder.
    Setyawan J, Yang H, Cheng D, Cai X, Signorovitch J, Xie J, Erder MH.
    Value Health; 2015 Sep; 18(6):824-31. PubMed ID: 26409610
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Post hoc analyses of the impact of previous medication on the efficacy of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in a randomized, controlled trial.
    Coghill DR, Banaschewski T, Lecendreux M, Soutullo C, Zuddas A, Adeyi B, Sorooshian S.
    Neuropsychiatr Dis Treat; 2014 Sep; 10():2039-47. PubMed ID: 25378930
    [Abstract] [Full Text] [Related]

  • 20. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder.
    Findling RL, Childress AC, Cutler AJ, Gasior M, Hamdani M, Ferreira-Cornwell MC, Squires L.
    J Am Acad Child Adolesc Psychiatry; 2011 Apr; 50(4):395-405. PubMed ID: 21421179
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.